Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260137 | 1.00 | KDM4E (0.36) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL22260135 | 1.00 | KDM4E (0.36) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL20833278 | 0.96 | KDM4E (0.40) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL22260075 | 0.96 | KDM4E (0.40) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL25980322 | 0.96 | KDM4E (0.40) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL20833273 | 0.96 | KDM4E (0.40) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL20833291 | 0.94 | KDM4E (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL25970770 | 0.94 | KDM4E (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL20833203 | 0.94 | KDM4E (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL22260146 | 0.90 | KDM4E (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | KDM4E 2103/4885NPC1 3712/4885CYP1A2 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.